Deutsche Bank AG purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 585,895 shares of the medical research company's stock, valued at approximately $124,180,000. Deutsche Bank AG owned 0.53% of Quest Diagnostics at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Key Financial Inc raised its holdings in shares of Quest Diagnostics by 1,728.6% during the first quarter. Key Financial Inc now owns 128 shares of the medical research company's stock valued at $25,000 after acquiring an additional 121 shares in the last quarter. Quattro Advisors LLC bought a new stake in Quest Diagnostics in the fourth quarter valued at $25,000. DV Equities LLC bought a new stake in Quest Diagnostics in the fourth quarter valued at $27,000. Sittner & Nelson LLC purchased a new position in Quest Diagnostics during the 4th quarter valued at $29,000. Finally, McIlrath & Eck LLC purchased a new position in Quest Diagnostics during the 4th quarter valued at $32,000. Institutional investors own 88.06% of the company's stock.
Quest Diagnostics Stock Up 2.3%
Shares of Quest Diagnostics stock opened at $241.78 on Thursday. The company has a 50-day simple moving average of $217.76 and a two-hundred day simple moving average of $204.48. The stock has a market capitalization of $26.69 billion, a PE ratio of 25.67, a price-to-earnings-growth ratio of 2.18 and a beta of 0.56. Quest Diagnostics Incorporated has a 52-week low of $171.18 and a 52-week high of $242.39. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59.
Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping analysts' consensus estimates of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the company earned $2.62 EPS. The company's quarterly revenue was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.
Quest Diagnostics Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics's dividend payout ratio is 36.52%.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on DGX shares. Jefferies Financial Group reissued a "buy" rating and issued a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. Weiss Ratings raised Quest Diagnostics from a "buy (b+)" rating to a "buy (a-)" rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded Quest Diagnostics from a "hold" rating to a "buy" rating in a report on Tuesday, July 28th. Robert W. Baird increased their target price on Quest Diagnostics from $236.00 to $255.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Finally, Truist Financial raised their target price on Quest Diagnostics from $225.00 to $250.00 and gave the company a "hold" rating in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $235.31.
Get Our Latest Analysis on Quest Diagnostics
Insider Buying and Selling
In other news, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the transaction, the senior vice president directly owned 10,335 shares of the company's stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the transaction, the senior vice president directly owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 19,747 shares of company stock valued at $3,947,088. 0.88% of the stock is owned by insiders.
Quest Diagnostics Profile
(
Free Report)
Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Quest Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.
While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
